News

Treating HIV-Infected Patients Cuts Sexual Transmission Rates


 

FROM THE INTERNATIONAL AIDS SOCIETY CONFERENCE ON HIV PATHOGENESIS AND TREATMENT

HPTN 052 was conducted by the HIV Prevention Trials Network, largely funded by NIAID, and also received funding from the National Institute on Drug Abuse and the National Institute of Mental Health; the AIDS Clinical Trials Group, funded by NIAID, also provided support for the study. The 11 antiretroviral drugs used in various combinations in the in the study were provided by the manufacturers, Abbott Laboratories; Boehringer Ingelheim Pharmaceuticals; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline/ViiV Healthcare; and Merck.

Pages

Recommended Reading

ACIP Keeps Current Recommendations For Zoster Vaccine
MDedge Internal Medicine
TB Prophylaxis Effective HIV-Infected Adults, but Not in Infants
MDedge Internal Medicine
FDA Approves Booster DTP Vaccine for Elderly
MDedge Internal Medicine
Ask Key Questions to Keep Travelers Healthy
MDedge Internal Medicine
Oral HIV Prophylaxis Slashes Heterosexual Infection Rates
MDedge Internal Medicine
Sepsis Mortality Rate Reduced by Antibiotics Prior to Shock Recognition
MDedge Internal Medicine
ACIP Considers Recommending PCV13 for Adults
MDedge Internal Medicine
Young Black Women Remain at Highest Risk for Herpes
MDedge Internal Medicine
No Increased Bone Risk Seen With HIV Treatments
MDedge Internal Medicine
This Season’s Flu Vaccine Is Same as Last
MDedge Internal Medicine